There's an old saying on Wall St, "never short a boring stock"; and you can't get more boring than this stock lately.
90% owned by institutions, and beyond this board almost no body knows about cabo; ASCO has to have a bombshell on OS or else we are doomed to trade in this 4.50 to 5.30 for the foreseeable future.
"...and beyond this board almost no body knows about cabo..."
I'd sure enjoy a repeat of the excitement that we saw in the wake of the bone phenom in Nov 2010. It interests me that the medical perception of cabo's onco-utility has grown in so geometric a fashion, the data continues to support the benefit of that effect, and yet so little recognition of the potential.
Whatever politics control EXEL - they appear strengthy, well-strategized, and solidly orchestrated. I can't escape the feeling that we are awaiting key patent expirations on competitive bone-tageting agents... the date of which triggers some nefarious plot of BP intrigue.
No...I didn't say we were being manipulated. I said we were being strangled...
I have a big position in PCYC (only position bigger than EXEL) and it's pleasant to contemplate a time when EXEL takes the ball in my portfolio from PCYC and runs with it. I believe that day will happen but it would be nice for it to happen ; 1) leading up to this years ASCO, or during it...how reassuring would that be?; and 2) to pass $5.31 and keep going thus putting pressure on the convertible folks to consider closing out their shorts. Just take the whole issue of the convertible offering off the table and make it, if not irrelevant, at least a part of the distant past as the stock moves into territory well above the convert price.